Cantor Fitzgerald Reiterates Overweight Rating on Lucid Diagnostics Inc (LUCD)

Cantor Fitzgerald analyst Ross Osborn reiterated an Overweight rating and $2.00 price target on Lucid Diagnostics Inc (NASDAQ: LUCD).

The analyst commented, “We reiterate our Overweight rating and 12-month $2 price target on Lucid Diagnostics (LUCD) following the company reporting comprehensive 4Q24 operating results and providing corporate updates. Specifically, LUCD reported 4Q24 revenue of $1.2 million (Cantor $1.7 million / FactSet Consensus $1.2 million), representing YoY growth of ~15%. Test volumes increased ~45% sequentially and ~84% YoY to 4,042 tests, driven by satellite testing (sLTC) activity and firefighter events. LUCD enters 2025 with strong momentum, supported by improved collections and payments, accelerating volumes, and reimbursement wins. Additionally, the company expects to receive an LCD decision in 1H25 to secure Medicare coverage for EsoGuard. Accordingly, we reiterate our OW rating on LUCD.”

For an analyst ratings summary and ratings history on Lucid Diagnostics Inc click here. For more ratings news on Lucid Diagnostics Inc click here.

Shares of Lucid Diagnostics Inc closed at $1.55 yesterday.

You May Also Be Interested In

• Waymo Explores Split With Uber - FT
• Jennifer Hyman to retire from Estee Lauder board in November
• NV Gold closes private placement, raises $868,071